{"paper_id":"2840bb8b-12e2-4885-b16d-ce56f7c9c77a","body_text":"Abstract\nObjective\nA meta-analysis was conducted to determine the effectiveness of using gonadotropin-releasing hormone analogues (GnRH-a), both with and without hormonal add-back therapy, for the management of endometriosis.\nMethods\nCochrane library, Ovid (Embase) and Pubmed databases were searched between the years 1998 and 2013 for published, prospective, randomised controlled trials (RCT) that assessed the effectiveness of “add-back” therapy for EMs treatment. The meta-analysis was performed using RevMan V5.0. The main outcome measures were as follows: lumbar spine bone mineral density (BMD) immediately after treatment and after 6 months of follow-up; femoral neck BMD; serum estradiol levels; changes in the Kupperman index score; the pelvic pain score, including dysmenorrhoea and dyspareunia; and pelvic tenderness.\nResults\nA total of 13 RCT, including 945 participants, were identified. The evidence suggested that “add-back” therapy was more effective for symptom relief than GnRH-a alone. BMD was significantly different when comparing “add-back” therapy to GnRH-a alone, both immediately after treatment and at 6 months. The “add-back” therapy increased serum oestrogen and did not reduce the efficacy of GnRH-a for treating dysmenorrhoea and dyspareunia. A variety of add-back regimens had a same effect for the treatment of endometriosis.\nConclusions\n“Add-back” therapy, based on the GnRH-a dose, does not reduce the efficacy of using GNRH-a for the management of endometriosis. “Add-back” therapy reduced the occurrence of side effects that can occur with GnRH-a therapy alone, such as osteoporosis and menopausal syndrome. There were no statistically significant differences when comparing the effectiveness of a variety of “add-back” regimens to each other.\nSimilar content being viewed by others\nReferences\nTekin Y, Dilbaz B, Altinbas SK et al (2011) Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril 95(2):492–496\nDenny E, Mann CH (2007) A clinical overview of endometriosis: a misunderstood disease. Br J Nurs 16(18):1112–1116\nKitawaki J, Kado N, Koshiba H, Honjo H (2002) Endometriosis: the pathophysiology as an estrogen-dependant disease. J Steroid Biochem Mol Biol 83:149–155\nSagsveen M, Farmer JE, Prentice A et al (2003) Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev (4):CD001297\nSurry ES, Silverberg KM, Surry MW et al (2002) Prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization–embryo transfer in patients with endometriosis. Fertil Steril 78(4):699–704\nWyatt KM, Dimmock PW, Ismail KMK et al (2004) The effectiveness of GnRHa with and without ‘add-back’ therapy in treating premenstrual syndrome: a meta analysis. BJOG 111(6):585–593\nAl-Azemi M, Jones G, Sirkeci F et al (2009) Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. BJOG 116:1646–1656\nFernandez H, Lucas C, HeÂdon B et al (2004) One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial. Hum Reprod 19(6):1465–1471\nFranke HR, van de Weijer PH, Pennings TM et al (2000) Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril 74(3):534–539\nGnoth CH, Gödtke K, Freundl G et al (1999) Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. Gynecol Obstet Invest 47:37–41\nHornstein MD, Surrey ES, Weisberg GW et al (1998) Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol 91(1):145–148\nHurst BS, Gardner SC, Tucker KE et al (2000) Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. JSLS 4:97–101\nIrahara M, Uemura H, Yasui T et al (2001) Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecol Obstet Invest 52:217–222\nLong QQ, Zhang SF, Han Y et al (2010) Clinical efficacy and safety of gonadotropin releasing hormone agonist combined with estrogen-dydrogesteronea in treatment of endometriosis. Chin J Obstet Gynecol 45(4):247–251\nMoghissi KS, Schlaff WD, Olive DL et al (1998) Goserelin acetate (Zoladex) with or without hormone replacement therapy for the treatment of endometriosis. Fertil Steril 69(6):1056–1062\nPierce S, Gazvani R, Farquharson R (2000) Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril 74(5):964–968\nSurrey E, Hornstein M (2002) Prolonged GnRH Agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 99(5):709–719\nWang YQ, Zhang SF, Chen X et al (2009) Effects and safety of gonadotrophin-releasing hormone agonist combined with estradiol patch and oral medroxyprogesterone acetate on endometriosis. Chin J Obstet Gynecol 44(7):504–508\nZupi E, Marconi D, Sbracia M et al (2004) Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril 82(5):1303–1308\nCedars M, Lu J, Meldrum D, Judd H (1990) Treatment of endometriosis with a long acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 75:641–645\nSurrey E, Gambone J, Lu J, Judd H (1990) The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 53:620–626\nNiu ZR, Yue XJ, Kong QY et al (2013) A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy. Zhonghua Fu Chan Ke Za Zhi 48(5):338–343\nCheung TH, Lo KW, Yim SF et al (2005) Dose effects of progesterone in add-back therapy during GnRHa treatment. J Reprod Med 50(1):35–40\nGuzick DS, Huang LS, Broadman BA et al (2011) Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 95(5):1568–1573\nConflict of interest\nThe authors declare that they have no conflict of interest.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nWu, D., Hu, M., Hong, L. et al. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis. Arch Gynecol Obstet 290, 513–523 (2014). https://doi.org/10.1007/s00404-014-3230-8\nReceived:\nAccepted:\nPublished:\nIssue date:\nDOI: https://doi.org/10.1007/s00404-014-3230-8","source_license":"CC0","license_restricted":false}